Literature DB >> 25805398

Uterine carcinosarcoma: A review of the literature.

Leigh A Cantrell1, Stephanie V Blank2, Linda R Duska3.   

Abstract

OBJECTIVE: Uterine carcinosarcomas (UCSs) are aggressive tumors previously considered to be sarcomas, but now recognized as malignancies composed of metaplastic transformation of epithelial elements. Much of the management for UCS has been extrapolated from studies of endometrial carcinomas and sarcomas. This article critically reviews the literature pertinent to the pathology, pathogenesis, diagnosis and management of women with UCS.
METHODS: MEDLINE was searched for English language literature on UCS with a focus on the past 20years. Given the rarity of this tumor, studies were not limited by design or number of reported patients.
RESULTS: UCS is biologically a de-differentiated endometrial carcinoma with its own pathogenesis and molecular profile. It commonly presents with extrauterine disease which can be identified by comprehensive surgical staging. Most UCS patients are candidates for adjuvant chemotherapy. The role of radiation is less clear. Combination therapy, while commonly used, has not been studied in depth. The high recurrence rate and poor overall survival for UCS suggest an ongoing need for clinical trials for UCS specifically.
CONCLUSIONS: UCS represents a distinct subtype of uterine malignancy, and should be studied as such via focused clinical trials.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinosarcoma; Endometrial; Mixed Mullerian; Sarcoma

Mesh:

Year:  2015        PMID: 25805398     DOI: 10.1016/j.ygyno.2015.03.041

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  60 in total

1.  Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study.

Authors:  Marco A C Versluis; Cindy Pielsticker; Maaike A van der Aa; Marco de Bruyn; Harry Hollema; Hans W Nijman
Journal:  Oncology       Date:  2018-05-23       Impact factor: 2.935

2.  L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.

Authors:  Mac Versluis; A Plat; M de Bruyn; X Matias-Guiu; J Trovic; C Krakstad; H W Nijman; T Bosse; G H de Bock; H Hollema
Journal:  Virchows Arch       Date:  2018-08-23       Impact factor: 4.064

3.  Molecular and clinicopathological analyses of esophageal carcinosarcoma with special reference to morphological change.

Authors:  Sho Tsuyama; Tsuyoshi Saito; Yoichi Akazawa; Yuka Yanai; Noboru Yatagai; Keisuke Akaike; Takuo Hayashi; Yoshiyuki Suehara; Fumiyuki Takahashi; Kazuya Takamochi; Takashi Hashimoto; Yoshiaki Kajiyama; Masahiko Tsurumaru; Tetsu Fukunaga; Takashi Yao
Journal:  Virchows Arch       Date:  2019-08-23       Impact factor: 4.064

4.  Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.

Authors:  Alba Mota; Eva Colás; Pablo García-Sanz; Irene Campoy; Alejandro Rojo-Sebastián; Sonia Gatius; Ángel García; Luis Chiva; Sonsoles Alonso; Antonio Gil-Moreno; Xavier González-Tallada; Berta Díaz-Feijoo; August Vidal; Patrycja Ziober-Malinowska; Marcin Bobiński; Rafael López-López; Miguel Abal; Jaume Reventós; Xavier Matias-Guiu; Gema Moreno-Bueno
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

5.  Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.

Authors:  Koji Matsuo; Kohei Omatsu; Malcolm S Ross; Marian S Johnson; Mayu Yunokawa; Merieme M Klobocista; Dwight D Im; Stephen H Bush; Yutaka Ueda; Tadao Takano; Erin A Blake; Kosei Hasegawa; Tsukasa Baba; Masako Shida; Shinya Satoh; Takuhei Yokoyama; Hiroko Machida; Sosuke Adachi; Yuji Ikeda; Keita Iwasaki; Takahito M Miyake; Shiori Yanai; Masato Nishimura; Tadayoshi Nagano; Munetaka Takekuma; Satoshi Takeuchi; Tanja Pejovic; Mian Mk Shahzad; Frederick R Ueland; Joseph L Kelley; Lynda D Roman
Journal:  Gynecol Oncol       Date:  2017-02-16       Impact factor: 5.482

6.  Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.

Authors:  Yavuz Emre Şükür; Salih Taşkın; Bulut Varlı; Can Ateş; Mete Güngör; Fırat Ortaç
Journal:  Int J Clin Oncol       Date:  2017-08-23       Impact factor: 3.402

7.  Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.

Authors:  Yohei Chiba; Seiya Sato; Hiroaki Itamochi; Yasuko Suga; Tomoyuki Fukagawa; Nao Oumi; Tetsuro Oishi; Tasuku Harada; Tamotsu Sugai; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-11-26       Impact factor: 4.174

8.  Uterine Sarcomas: Experience from a Tertiary Cancer Care Center from India.

Authors:  Syed Nusrath; Sandeep Bafna; R Rajagopalan; Subramanyeshwar Rao Thammineedi; K V V N Raju; Sujit Chyau Patnaik; Satish Pawar; Yugandhar Reddy; Ramachandra Nagaraju Chavali; Sudha S Murthy
Journal:  Indian J Surg Oncol       Date:  2019-01-05

Review 9.  Biphasic malignant tumours of the abdominal cavity.

Authors:  L Max Almond; Adrian T Warfield; Anant Desai; David Gourevitch; Samuel J Ford
Journal:  Int J Clin Oncol       Date:  2017-06-27       Impact factor: 3.402

10.  Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.

Authors:  Xiaofan Lu; Liya Zhang; Huiling Zhao; Chen Chen; Yaoyan Wang; Shengjie Liu; Xiao Lin; Yue Wang; Qianyuan Zhang; Tao Lu; Fangrong Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.